Product Information
for Physicians
(PDF 1.190 MB)

CANASA^® Pac

6 Weeks of Therapy with CANASA^® Is Proven Effective in Resolving Symptoms^1,2

Now Available as a 6-Week Course of Therapy, CANASA^® Pac Provides:

• More convenient option for moderate-severe ulcerative proctitis
• Same accelerated symptom relief¹
  • Significantly reduces stool frequency, diarrhea and tenesmus^1,*
  • Reduces urgency associated with tenesmus³
  • Improves rectal bleeding^4,5
• Studies have suggested that CANASA^® may help avoid relapse after 6-weeks of treatment¹

  ^*Compared to placebo

After 6 Weeks of Treatment with CANASA^® 1000 mg Suppositories, 86% of Patients Achieved a Substantial Improvement in DAI Scores¹

• Disease Activity Index (DAI) measures stool frequency, rectal mucosal appearance and disease global assessment^1,2
• Improvement was defined as a DAI score of less than 3¹

  Primary Outcome Disease Activity Index with CANASA^® 1000 mg Suppository²

  

  Secondary DAI Components²

  

"In view of their high efficacy and low side effect rates, 5-ASA suppositories are first-line therapy for UP."⁶

- Clinical Guidelines for the Medical Management of Left-Sided Ulcerative Colitis and Ulcerative Proctitis

Ulcerative Proctitis Management Algorithm⁶

Adapted from the Clinical Guidelines for the Medical Management of Left-Sided Ulcerative Colitis and Ulcerative Proctitis

Inflamm Bowel Dis Volume 12, Number 10, October 2006

Topical Is More Effective than Oral Therapy for Reducing Rectal Bleeding in Proctitis⁷

After 6 Weeks of Therapy, Cessation of Rectal Bleeding was Achieved In:

• 90% of combination topical plus oral treated patients⁷
• 56% of topical mesalamine-treated patients⁷
• 36% of oral mesalamine-treated patients⁷

Cessation of Rectal Bleeding with Distal Colitis Therapy (week 6)⁷

* References

^® Registered trademarks and ™ trademarks are used under license by Axcan Pharma US, Inc.